Why the study?
Cancer therapy-induced cardiotoxicity has become a defining challenge of modern oncology as cancer survival improves.
Long non-coding RNAs regulate key pathophysiologic pathways in cancer therapy-induced cardiotoxicity and represent promising future biomarkers and targets for RNA-guided cardioprotection.
Cancer therapies save lives but often “break hearts” by damaging the cardiovascular system. As survival improves, therapy-induced cardiotoxicity has become a defining challenge of modern oncology. Recent discoveries reveal that long non-coding RNAs (lncRNAs), once dismissed as genomic noise, are the “RNA rebels” orchestrating cellular responses to cancer treatments. These molecules act as both heartbreakers and healers, amplifying or counteracting oxidative stress, mitochondrial dysfunction, apoptosis, and vascular injury. In anthracycline, radiation, and VEGF-targeted therapies, lncRNAs govern key processes that dictate whether cells succumb to damage or mount protective repair responses. Pro-injury lncRNAs exacerbate senescence and inflammation, while protective ones preserve mitochondrial homeostasis and limit cell death. Beyond mechanistic insight, these molecules hold clinical promise as biomarkers and therapeutic targets, guiding RNA-based strategies to predict, prevent, and treat cardiotoxicity. Understanding how they blur the line between protection and harm may redefine how we safeguard the heart in the era of precision cardio oncology. • Cancer survivorship has unveiled a new cardiovascular frontier, where therapy-induced cardiotoxicity threatens long-term health. • Different cancer therapies converge on shared injury pathways, including oxidative stress, mitochondrial dysfunction, and inflammation. • Endothelial dysfunction emerges as the earliest and most unifying driver of microvascular rarefaction and cardiac vulnerability. • Cross-talk between vascular and myocardial cells forms the mechanistic core of therapy-induced cardiovascular damage. • Long non-coding RNAs (lncRNAs) redefine cardiotoxicity, acting as key regulators of stress response, angiogenesis, and remodeling. • Circulating and tissue-specific lncRNAs are promising biomarkers and therapeutic targets for RNA-guided cardioprotection. • Integrative RNA-based and vascular models will drive precision strategies to prevent and treat therapy-induced cardiovascular disease.
No takes yet. Share an insight, caveat, or question.
Agyemang-Dua et al. (2025) conducted a review in Therapy-induced cardiotoxicity. Cancer therapies (anthracyclines, radiation, VEGF-TKIs) and long non-coding RNAs (lncRNAs) was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: